> top > docs > PubMed:26351076 > annotations

PubMed:26351076 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
26351076-0#0#5#gene6772 481-486 gene6772 denotes STAT1
26351076-0#66#77#diseaseC0242379 1801-1812 diseaseC0242379 denotes lung cancer
26351076-0#66#77#diseaseC0684249 1801-1812 diseaseC0684249 denotes lung cancer
26351076-0#66#77#diseaseC1306460 1801-1812 diseaseC1306460 denotes lung cancer
26351076-3#167#170#gene5541 557-560 gene5541 denotes SPC
26351076-3#167#170#gene114131 557-560 gene114131 denotes SPC
26351076-3#0#50#gene6772 390-440 gene6772 denotes Signal Transducer and Activator of Transcription 1
26351076-3#52#57#gene6772 442-447 gene6772 denotes STAT1
26351076-3#73#78#gene6772 463-468 gene6772 denotes STAT1
26351076-3#91#96#gene6772 481-486 gene6772 denotes STAT1
26351076-3#155#166#diseaseC0242379 545-556 diseaseC0242379 denotes lung cancer
26351076-3#155#166#diseaseC0684249 545-556 diseaseC0684249 denotes lung cancer
26351076-3#155#166#diseaseC1306460 545-556 diseaseC1306460 denotes lung cancer
26351076-3#155#166#diseaseC0242379 545-556 diseaseC0242379 denotes lung cancer
26351076-3#155#166#diseaseC0684249 545-556 diseaseC0684249 denotes lung cancer
26351076-3#155#166#diseaseC1306460 545-556 diseaseC1306460 denotes lung cancer
26351076-3#109#114#diseaseC0424295 499-504 diseaseC0424295 denotes hyper
26351076-8#80#85#gene3456 1349-1354 gene3456 denotes IFN-β
26351076-8#109#120#diseaseC0242379 1378-1389 diseaseC0242379 denotes lung cancer
26351076-8#109#120#diseaseC0684249 1378-1389 diseaseC0684249 denotes lung cancer
26351076-8#109#120#diseaseC1306460 1378-1389 diseaseC1306460 denotes lung cancer
0#5#gene677266#77#diseaseC0242379 26351076-0#0#5#gene6772 26351076-0#66#77#diseaseC0242379 associated_with STAT1,lung cancer
0#5#gene677266#77#diseaseC0684249 26351076-0#0#5#gene6772 26351076-0#66#77#diseaseC0684249 associated_with STAT1,lung cancer
0#5#gene677266#77#diseaseC1306460 26351076-0#0#5#gene6772 26351076-0#66#77#diseaseC1306460 associated_with STAT1,lung cancer
167#170#gene5541155#166#diseaseC0242379 26351076-3#167#170#gene5541 26351076-3#155#166#diseaseC0242379 associated_with SPC,lung cancer
167#170#gene5541155#166#diseaseC0684249 26351076-3#167#170#gene5541 26351076-3#155#166#diseaseC0684249 associated_with SPC,lung cancer
167#170#gene5541155#166#diseaseC1306460 26351076-3#167#170#gene5541 26351076-3#155#166#diseaseC1306460 associated_with SPC,lung cancer
167#170#gene5541155#166#diseaseC0242379 26351076-3#167#170#gene5541 26351076-3#155#166#diseaseC0242379 associated_with SPC,lung cancer
167#170#gene5541155#166#diseaseC0684249 26351076-3#167#170#gene5541 26351076-3#155#166#diseaseC0684249 associated_with SPC,lung cancer
167#170#gene5541155#166#diseaseC1306460 26351076-3#167#170#gene5541 26351076-3#155#166#diseaseC1306460 associated_with SPC,lung cancer
167#170#gene5541109#114#diseaseC0424295 26351076-3#167#170#gene5541 26351076-3#109#114#diseaseC0424295 associated_with SPC,hyper
167#170#gene114131155#166#diseaseC0242379 26351076-3#167#170#gene114131 26351076-3#155#166#diseaseC0242379 associated_with SPC,lung cancer
167#170#gene114131155#166#diseaseC0684249 26351076-3#167#170#gene114131 26351076-3#155#166#diseaseC0684249 associated_with SPC,lung cancer
167#170#gene114131155#166#diseaseC1306460 26351076-3#167#170#gene114131 26351076-3#155#166#diseaseC1306460 associated_with SPC,lung cancer
167#170#gene114131155#166#diseaseC0242379 26351076-3#167#170#gene114131 26351076-3#155#166#diseaseC0242379 associated_with SPC,lung cancer
167#170#gene114131155#166#diseaseC0684249 26351076-3#167#170#gene114131 26351076-3#155#166#diseaseC0684249 associated_with SPC,lung cancer
167#170#gene114131155#166#diseaseC1306460 26351076-3#167#170#gene114131 26351076-3#155#166#diseaseC1306460 associated_with SPC,lung cancer
167#170#gene114131109#114#diseaseC0424295 26351076-3#167#170#gene114131 26351076-3#109#114#diseaseC0424295 associated_with SPC,hyper
0#50#gene6772155#166#diseaseC0242379 26351076-3#0#50#gene6772 26351076-3#155#166#diseaseC0242379 associated_with Signal Transducer and Activator of Transcription 1,lung cancer
0#50#gene6772155#166#diseaseC0684249 26351076-3#0#50#gene6772 26351076-3#155#166#diseaseC0684249 associated_with Signal Transducer and Activator of Transcription 1,lung cancer
0#50#gene6772155#166#diseaseC1306460 26351076-3#0#50#gene6772 26351076-3#155#166#diseaseC1306460 associated_with Signal Transducer and Activator of Transcription 1,lung cancer
0#50#gene6772155#166#diseaseC0242379 26351076-3#0#50#gene6772 26351076-3#155#166#diseaseC0242379 associated_with Signal Transducer and Activator of Transcription 1,lung cancer
0#50#gene6772155#166#diseaseC0684249 26351076-3#0#50#gene6772 26351076-3#155#166#diseaseC0684249 associated_with Signal Transducer and Activator of Transcription 1,lung cancer
0#50#gene6772155#166#diseaseC1306460 26351076-3#0#50#gene6772 26351076-3#155#166#diseaseC1306460 associated_with Signal Transducer and Activator of Transcription 1,lung cancer
0#50#gene6772109#114#diseaseC0424295 26351076-3#0#50#gene6772 26351076-3#109#114#diseaseC0424295 associated_with Signal Transducer and Activator of Transcription 1,hyper
52#57#gene6772155#166#diseaseC0242379 26351076-3#52#57#gene6772 26351076-3#155#166#diseaseC0242379 associated_with STAT1,lung cancer
52#57#gene6772155#166#diseaseC0684249 26351076-3#52#57#gene6772 26351076-3#155#166#diseaseC0684249 associated_with STAT1,lung cancer
52#57#gene6772155#166#diseaseC1306460 26351076-3#52#57#gene6772 26351076-3#155#166#diseaseC1306460 associated_with STAT1,lung cancer
52#57#gene6772155#166#diseaseC0242379 26351076-3#52#57#gene6772 26351076-3#155#166#diseaseC0242379 associated_with STAT1,lung cancer
52#57#gene6772155#166#diseaseC0684249 26351076-3#52#57#gene6772 26351076-3#155#166#diseaseC0684249 associated_with STAT1,lung cancer
52#57#gene6772155#166#diseaseC1306460 26351076-3#52#57#gene6772 26351076-3#155#166#diseaseC1306460 associated_with STAT1,lung cancer
52#57#gene6772109#114#diseaseC0424295 26351076-3#52#57#gene6772 26351076-3#109#114#diseaseC0424295 associated_with STAT1,hyper
73#78#gene6772155#166#diseaseC0242379 26351076-3#73#78#gene6772 26351076-3#155#166#diseaseC0242379 associated_with STAT1,lung cancer
73#78#gene6772155#166#diseaseC0684249 26351076-3#73#78#gene6772 26351076-3#155#166#diseaseC0684249 associated_with STAT1,lung cancer
73#78#gene6772155#166#diseaseC1306460 26351076-3#73#78#gene6772 26351076-3#155#166#diseaseC1306460 associated_with STAT1,lung cancer
73#78#gene6772155#166#diseaseC0242379 26351076-3#73#78#gene6772 26351076-3#155#166#diseaseC0242379 associated_with STAT1,lung cancer
73#78#gene6772155#166#diseaseC0684249 26351076-3#73#78#gene6772 26351076-3#155#166#diseaseC0684249 associated_with STAT1,lung cancer
73#78#gene6772155#166#diseaseC1306460 26351076-3#73#78#gene6772 26351076-3#155#166#diseaseC1306460 associated_with STAT1,lung cancer
73#78#gene6772109#114#diseaseC0424295 26351076-3#73#78#gene6772 26351076-3#109#114#diseaseC0424295 associated_with STAT1,hyper
91#96#gene6772155#166#diseaseC0242379 26351076-3#91#96#gene6772 26351076-3#155#166#diseaseC0242379 associated_with STAT1,lung cancer
91#96#gene6772155#166#diseaseC0684249 26351076-3#91#96#gene6772 26351076-3#155#166#diseaseC0684249 associated_with STAT1,lung cancer
91#96#gene6772155#166#diseaseC1306460 26351076-3#91#96#gene6772 26351076-3#155#166#diseaseC1306460 associated_with STAT1,lung cancer
91#96#gene6772155#166#diseaseC0242379 26351076-3#91#96#gene6772 26351076-3#155#166#diseaseC0242379 associated_with STAT1,lung cancer
91#96#gene6772155#166#diseaseC0684249 26351076-3#91#96#gene6772 26351076-3#155#166#diseaseC0684249 associated_with STAT1,lung cancer
91#96#gene6772155#166#diseaseC1306460 26351076-3#91#96#gene6772 26351076-3#155#166#diseaseC1306460 associated_with STAT1,lung cancer
91#96#gene6772109#114#diseaseC0424295 26351076-3#91#96#gene6772 26351076-3#109#114#diseaseC0424295 associated_with STAT1,hyper
80#85#gene3456109#120#diseaseC0242379 26351076-8#80#85#gene3456 26351076-8#109#120#diseaseC0242379 associated_with IFN-β,lung cancer
80#85#gene3456109#120#diseaseC0684249 26351076-8#80#85#gene3456 26351076-8#109#120#diseaseC0684249 associated_with IFN-β,lung cancer
80#85#gene3456109#120#diseaseC1306460 26351076-8#80#85#gene3456 26351076-8#109#120#diseaseC1306460 associated_with IFN-β,lung cancer

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T2373 0-5 gene:6772 denotes STAT1
T2374 66-77 disease:C0242379 denotes lung cancer
T2375 557-560 gene:5541 denotes SPC
T2376 545-556 disease:C0242379 denotes lung cancer
T2379 1349-1354 gene:3456 denotes IFN-β
T2380 1378-1389 disease:C0242379 denotes lung cancer
R1 T2373 T2374 associated_with STAT1,lung cancer
R2 T2373 T2374 associated_with STAT1,lung cancer
R3 T2373 T2374 associated_with STAT1,lung cancer
R4 T2375 T2376 associated_with SPC,lung cancer
R5 T2375 T2376 associated_with SPC,lung cancer
R6 T2375 T2376 associated_with SPC,lung cancer
R7 T2375 T2376 associated_with SPC,lung cancer
R8 T2375 T2376 associated_with SPC,lung cancer
R9 T2375 T2376 associated_with SPC,lung cancer
R1 T2379 T2380 associated_with IFN-β,lung cancer
R2 T2379 T2380 associated_with IFN-β,lung cancer
R3 T2379 T2380 associated_with IFN-β,lung cancer

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-84 Sentence denotes STAT1 modification improves therapeutic effects of interferons on lung cancer cells.
TextSentencer_T2 85-96 Sentence denotes BACKGROUND:
TextSentencer_T3 97-210 Sentence denotes Interferons (IFNs) have potent anti-proliferative, pro-apoptotic, and immunomodulatory activities against cancer.
TextSentencer_T4 211-380 Sentence denotes However, the clinical utility of IFNs is limited by toxicity and pharmacokinetics making it difficult to achieve sustained therapeutic levels especially in solid tumors.
TextSentencer_T5 381-389 Sentence denotes METHODS:
TextSentencer_T6 390-606 Sentence denotes Signal Transducer and Activator of Transcription 1 (STAT1) or a modified STAT1 (designated STAT1-CC) that is hyper-responsive to IFN were overexpressed in lung cancer SPC-A-1 and H1299 cells using lentiviral vectors.
TextSentencer_T7 607-704 Sentence denotes Transduction efficiency was monitored using enhanced green fluorescent protein (EGFP) expression.
TextSentencer_T8 705-984 Sentence denotes After transduction, cells were treated with interferon-gamma (IFN-γ) or interferon-beta (IFN-β) and monitored for cell proliferation, migration, and invasiveness using Cell Counting Kit-8 and transwell chamber assays and for apoptosis using Annexin V detection by flow cytometry.
TextSentencer_T9 985-1121 Sentence denotes In addition, levels of STAT1, STAT1 Tyr-701 phosphorylation (pSTAT1), fibronectin, and β-catenin were determined using western blotting.
TextSentencer_T10 1122-1259 Sentence denotes In the case of IFN-γ stimulation, levels of S100A4, proliferating cell nuclear antigen (PCNA), and c-fos expression were also determined.
TextSentencer_T11 1260-1268 Sentence denotes RESULTS:
TextSentencer_T12 1269-1437 Sentence denotes We found that expression of STAT1 or STAT1-CC enhanced the effect of IFN-γ and, IFN-β on inhibition of human lung cancer cell proliferation, migration and invasiveness.
TextSentencer_T13 1438-1555 Sentence denotes Moreover, STAT1 and STAT1-CC expression caused increases in pSTAT1 and decreases in fibronectin and β-catenin levels.
TextSentencer_T14 1556-1686 Sentence denotes STAT1-CC showed increased effects compared to STAT1 on IFN-γ induced pSTAT1 and down-regulation of S100A4, PCNA, and c-fos levels.
TextSentencer_T15 1687-1698 Sentence denotes CONCLUSION:
TextSentencer_T16 1699-1819 Sentence denotes The results show that STAT1-CC exhibited more strength in improving the antitumor response of IFNs in lung cancer cells.
TextSentencer_T17 1820-1983 Sentence denotes Results from this study suggest that combined treatment of IFNs and STAT1-CC might be a feasible approach for the clinical management of lung cancer in the future.
T1 0-84 Sentence denotes STAT1 modification improves therapeutic effects of interferons on lung cancer cells.
T2 85-96 Sentence denotes BACKGROUND:
T3 97-210 Sentence denotes Interferons (IFNs) have potent anti-proliferative, pro-apoptotic, and immunomodulatory activities against cancer.
T4 211-380 Sentence denotes However, the clinical utility of IFNs is limited by toxicity and pharmacokinetics making it difficult to achieve sustained therapeutic levels especially in solid tumors.
T5 381-389 Sentence denotes METHODS:
T6 390-606 Sentence denotes Signal Transducer and Activator of Transcription 1 (STAT1) or a modified STAT1 (designated STAT1-CC) that is hyper-responsive to IFN were overexpressed in lung cancer SPC-A-1 and H1299 cells using lentiviral vectors.
T7 607-704 Sentence denotes Transduction efficiency was monitored using enhanced green fluorescent protein (EGFP) expression.
T8 705-984 Sentence denotes After transduction, cells were treated with interferon-gamma (IFN-γ) or interferon-beta (IFN-β) and monitored for cell proliferation, migration, and invasiveness using Cell Counting Kit-8 and transwell chamber assays and for apoptosis using Annexin V detection by flow cytometry.
T9 985-1121 Sentence denotes In addition, levels of STAT1, STAT1 Tyr-701 phosphorylation (pSTAT1), fibronectin, and β-catenin were determined using western blotting.
T10 1122-1259 Sentence denotes In the case of IFN-γ stimulation, levels of S100A4, proliferating cell nuclear antigen (PCNA), and c-fos expression were also determined.
T11 1260-1268 Sentence denotes RESULTS:
T12 1269-1437 Sentence denotes We found that expression of STAT1 or STAT1-CC enhanced the effect of IFN-γ and, IFN-β on inhibition of human lung cancer cell proliferation, migration and invasiveness.
T13 1438-1555 Sentence denotes Moreover, STAT1 and STAT1-CC expression caused increases in pSTAT1 and decreases in fibronectin and β-catenin levels.
T14 1556-1686 Sentence denotes STAT1-CC showed increased effects compared to STAT1 on IFN-γ induced pSTAT1 and down-regulation of S100A4, PCNA, and c-fos levels.
T15 1687-1698 Sentence denotes CONCLUSION:
T16 1699-1819 Sentence denotes The results show that STAT1-CC exhibited more strength in improving the antitumor response of IFNs in lung cancer cells.
T17 1820-1983 Sentence denotes Results from this study suggest that combined treatment of IFNs and STAT1-CC might be a feasible approach for the clinical management of lung cancer in the future.

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 66-70 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 545-549 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T3 1378-1382 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T4 1801-1805 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T5 1957-1961 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 66-70 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T2 545-549 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T3 1378-1382 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T4 1801-1805 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung
PD-UBERON-AE-B_T5 1957-1961 http://purl.obolibrary.org/obo/UBERON_0002048 denotes lung